Pub Date : 2025-07-01DOI: 10.1016/j.remn.2024.500080
M.N. Acar Tayyar , M.Ö. Tamam , G.B. Babacan , M.C. Şahin , H. Özçevik , S. Şengiz Erhan , A.E. Öztürk
Objective
Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [18F]FDG PET/CT and to investigate its impact on survival.
Methods
Pretreatment metabolic parameters measured by [18F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients. The relationship between pathological data, tumor metabolic characteristics, and distant metastases was examined, and the effect on survival was investigated.
Results
Among the 117 patients, 17.1% were HER2-positive (HER2+), and 82.9% were HER2-negative (HER2−). There was no significant association between PET/CT parameters in the HER2+ and HER2− patient groups. HER2+ patients had higher 1- and 3-year survival expectations than HER2− patients (80-37.9%; 47.5-20%; respectively). There was no statistically significant difference in overall survival. In Cox-regression analysis, while the presence of vascular invasion, local invasion, and distant metastasis were poor prognostic factors, HER2 was not a prognostic factor. Vascular invasion and local invasion (T3/T4) were also associated with higher SUVmax values. Patients with distant metastases had significantly higher SUVmax, SUVmean, and TLG.
Conclusion
This study showed no association between HER2 expression and [18F]FDG PET/CT metabolic parameters. However, regardless of HER2 status, the results indicated distant metastasis, local invasion, and vascular invasion could be associated with primary tumor metabolism. PET/CT parameters predict tumor aggressiveness and disease prognosis better than HER2 status.
{"title":"Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos","authors":"M.N. Acar Tayyar , M.Ö. Tamam , G.B. Babacan , M.C. Şahin , H. Özçevik , S. Şengiz Erhan , A.E. Öztürk","doi":"10.1016/j.remn.2024.500080","DOIUrl":"10.1016/j.remn.2024.500080","url":null,"abstract":"<div><h3>Objective</h3><div>Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [<sup>18</sup>F]FDG PET/CT and to investigate its impact on survival.</div></div><div><h3>Methods</h3><div>Pretreatment metabolic parameters measured by [<sup>18</sup>F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients. The relationship between pathological data, tumor metabolic characteristics, and distant metastases was examined, and the effect on survival was investigated.</div></div><div><h3>Results</h3><div>Among the 117 patients, 17.1% were HER2-positive (HER2<sup>+</sup>), and 82.9% were HER2-negative (HER2<sup>−</sup>). There was no significant association between PET/CT parameters in the HER2<sup>+</sup> and HER2<sup>−</sup> patient groups. HER2<sup>+</sup> patients had higher 1- and 3-year survival expectations than HER2<sup>−</sup> patients (80-37.9%; 47.5-20%; respectively). There was no statistically significant difference in overall survival. In Cox-regression analysis, while the presence of vascular invasion, local invasion, and distant metastasis were poor prognostic factors, HER2 was not a prognostic factor. Vascular invasion and local invasion (T3/T4) were also associated with higher SUVmax values. Patients with distant metastases had significantly higher SUVmax, SUVmean, and TLG.</div></div><div><h3>Conclusion</h3><div>This study showed no association between HER2 expression and [<sup>18</sup>F]FDG PET/CT metabolic parameters. However, regardless of HER2 status, the results indicated distant metastasis, local invasion, and vascular invasion could be associated with primary tumor metabolism. PET/CT parameters predict tumor aggressiveness and disease prognosis better than HER2 status.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 4","pages":"Article 500080"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.remn.2025.500161
I. Torres , R. Ramos , M.L. Domínguez , J.J. Rosales , A. Roteta , E. Prieto , L. Sancho , M. de Arcocha , G. Quincoces , en nombre del Grupo de Oncología de la SEMNIM
In this third installment of the continuing education series, the clinical and therapeutic applications of zirconium, astatine and thorium are analyzed in depth. Although they are not described as theragnostic pairs, each of these radionuclides plays a fundamental role in precision medicine, which is rapidly advancing within Nuclear Medicine.
We begin by analyzing zirconium-89, a positron emitter whose long half-life makes it particularly suitable for labeling large molecules with slow kinetics, such as antibodies, playing a crucial role in immunotherapy. The use of astatine-211, an alpha-emitting radionuclide with a simple decay scheme and chemical behavior similar to iodine, is also discussed. Its main challenge lies in its production, as it requires cyclotrons capable of generating highly energetic alpha particle beams. Furthermore, thorium-227, a 100% alpha emitter, is reviewed. This radionuclide exhibits excellent chelation properties, enabling its conjugation with tumor-targeting molecules to produce thorium-labeled conjugates. While this technique is yielding promising preclinical results, the use of thorium faces challenges, including the potential separation of radium-223 from the molecule and the dependence of activity measurements on the time of production. Since it takes 100 days to reach equilibrium, activity assessment is based on photons emitted by its daughter radionuclides.
Despite these challenges, these radionuclides are driving the evolution of precision medicine, expanding therapeutic and diagnostic possibilities within Nuclear Medicine.
{"title":"Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte III","authors":"I. Torres , R. Ramos , M.L. Domínguez , J.J. Rosales , A. Roteta , E. Prieto , L. Sancho , M. de Arcocha , G. Quincoces , en nombre del Grupo de Oncología de la SEMNIM","doi":"10.1016/j.remn.2025.500161","DOIUrl":"10.1016/j.remn.2025.500161","url":null,"abstract":"<div><div>In this third installment of the continuing education series, the clinical and therapeutic applications of zirconium, astatine and thorium are analyzed in depth. Although they are not described as theragnostic pairs, each of these radionuclides plays a fundamental role in precision medicine, which is rapidly advancing within Nuclear Medicine.</div><div>We begin by analyzing zirconium-89, a positron emitter whose long half-life makes it particularly suitable for labeling large molecules with slow kinetics, such as antibodies, playing a crucial role in immunotherapy. The use of astatine-211, an alpha-emitting radionuclide with a simple decay scheme and chemical behavior similar to iodine, is also discussed. Its main challenge lies in its production, as it requires cyclotrons capable of generating highly energetic alpha particle beams. Furthermore, thorium-227, a 100% alpha emitter, is reviewed. This radionuclide exhibits excellent chelation properties, enabling its conjugation with tumor-targeting molecules to produce thorium-labeled conjugates. While this technique is yielding promising preclinical results, the use of thorium faces challenges, including the potential separation of radium-223 from the molecule and the dependence of activity measurements on the time of production. Since it takes 100 days to reach equilibrium, activity assessment is based on photons emitted by its daughter radionuclides.</div><div>Despite these challenges, these radionuclides are driving the evolution of precision medicine, expanding therapeutic and diagnostic possibilities within Nuclear Medicine.</div><div>Nuclear Medicine.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 4","pages":"Article 500161"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.remn.2024.500091
S. Casanueva-Eliceiry , M. Manyalich-Blasi , A. Farré-Melero , A. Niñerola-Baizán , D. Saavedra , M. Mora-Porta , F.A. Hanzu , A. Orois , M. Squarcia , M. Rodrigo-Calvo , M. Tormo-Ratera , K. Quintero-Martinez , D. Fuster-Pelfort , O. Vidal-Pérez , S. Vidal-Sicart
Background and objectives
To compare the diagnostic accuracy of [18F]-Fluorocholine (FCH) PET/CT with conventional [99mTc]Tc-MIBI scintigraphy and cervical ultrasound (USG) for the preoperative localization of hyperfunctioning parathyroid tissue (HFPT) in patients with primary hyperparathyroidism (PHPT).
Materials and methods
This prospective study included 90 patients diagnosed with PHPT who underwent [18F]F-CH PET/CT, [99mTc]Tc-MIBI SPECT/CT and Neck USG. The diagnostic accuracy of each imaging modality was assessed using intraoperative findings and histopathological confirmation as the gold standard. The localization accuracy was evaluated based on specific quadrant detection, laterality, and ectopic gland identification. The study also explored the correlation between imaging findings and biochemical parameters, including preoperative and postoperative PTH and calcium levels.
Results
[18F]F-CH PET/CT demonstrated superior accuracy in detecting pathological parathyroid glandscompared to [99mTc]Tc-MIBI SPECT/CT and USG. [18F]F-CH PET/CT correctly identified 98.9% of patientswith pathological glands, with a specific location accuracy of 93.2%, 65.9% and 38.8% for [18F]F-CH PET/CT,[99mTc]Tc-MIBI SPECT/CT and USG, respectively.
For ectopic adenomas, FCH PET/CT achieved an accuracy of 100% (4/4), while MIBI and neck ultrasound identified these in 50% (2/4) and 0% (0/4) of cases, respectively.
There were two cases of multiglandular disease, [18F]F-CH PET/CT and [99mTc]Tc-MIBI each detected one gland in one case (50%) while USG detected none; in the other case, [18F]F-CH PET/CT and USG identified both glands (100%), and [99mTc]Tc-MIBI detected none.
Significant correlations were observed between SUVmax values from [18F]F-CH PET/CT and gland size, weight, and preoperative PTH levels.
Conclusions
[18F]F-CH PET/CT outperformed conventional imaging modalities in the preoperative localization of HFPT, particularly in challenging cases such ectopic or multiglandular disease. These findings support its potential as an effective and reliable imaging tool for the management of primary hyperparathyroidism.
{"title":"Redefiniendo la localización preoperatoria basada en imágenes de los adenomas en pacientes con hiperparatiroidismo primario candidatos a cirugía mínimamente invasiva","authors":"S. Casanueva-Eliceiry , M. Manyalich-Blasi , A. Farré-Melero , A. Niñerola-Baizán , D. Saavedra , M. Mora-Porta , F.A. Hanzu , A. Orois , M. Squarcia , M. Rodrigo-Calvo , M. Tormo-Ratera , K. Quintero-Martinez , D. Fuster-Pelfort , O. Vidal-Pérez , S. Vidal-Sicart","doi":"10.1016/j.remn.2024.500091","DOIUrl":"10.1016/j.remn.2024.500091","url":null,"abstract":"<div><h3>Background and objectives</h3><div>To compare the diagnostic accuracy of [<sup>18</sup>F]-Fluorocholine (FCH) PET/CT with conventional [<sup>99m</sup>Tc]Tc-MIBI scintigraphy and cervical ultrasound (USG) for the preoperative localization of hyperfunctioning parathyroid tissue (HFPT) in patients with primary hyperparathyroidism (PHPT).</div></div><div><h3>Materials and methods</h3><div>This prospective study included 90 patients diagnosed with PHPT who underwent [<sup>18</sup>F]F-CH PET/CT, [<sup>99m</sup>Tc]Tc-MIBI SPECT/CT and Neck USG. The diagnostic accuracy of each imaging modality was assessed using intraoperative findings and histopathological confirmation as the gold standard. The localization accuracy was evaluated based on specific quadrant detection, laterality, and ectopic gland identification. The study also explored the correlation between imaging findings and biochemical parameters, including preoperative and postoperative PTH and calcium levels.</div></div><div><h3>Results</h3><div>[<sup>18</sup>F]F-CH PET/CT demonstrated superior accuracy in detecting pathological parathyroid glandscompared to [<sup>99m</sup>Tc]Tc-MIBI SPECT/CT and USG. [<sup>18</sup>F]F-CH PET/CT correctly identified 98.9% of patientswith pathological glands, with a specific location accuracy of 93.2%, 65.9% and 38.8% for [<sup>18</sup>F]F-CH PET/CT,[<sup>99m</sup>Tc]Tc-MIBI SPECT/CT and USG, respectively.</div><div>For ectopic adenomas, FCH PET/CT achieved an accuracy of 100% (4/4), while MIBI and neck ultrasound identified these in 50% (2/4) and 0% (0/4) of cases, respectively.</div><div>There were two cases of multiglandular disease, [<sup>18</sup>F]F-CH PET/CT and [99mTc]Tc-MIBI each detected one gland in one case (50%) while USG detected none; in the other case, [<sup>18</sup>F]F-CH PET/CT and USG identified both glands (100%), and [99mTc]Tc-MIBI detected none.</div><div>Significant correlations were observed between SUVmax values from [<sup>18</sup>F]F-CH PET/CT and gland size, weight, and preoperative PTH levels.</div></div><div><h3>Conclusions</h3><div>[<sup>18</sup>F]F-CH PET/CT outperformed conventional imaging modalities in the preoperative localization of HFPT, particularly in challenging cases such ectopic or multiglandular disease. These findings support its potential as an effective and reliable imaging tool for the management of primary hyperparathyroidism.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 4","pages":"Article 500091"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-24DOI: 10.1016/j.remn.2025.500112
G.B. Babacan , M.Ö. Tamam , S. Saraçoğlu , M.N. Acar Tayyar , M.C. Şahin , H. Özçevik , G. Kulduk , Ö.B. Ekinci , E. Çelik
Objective
This study aimed to investigate the relationship between semiquantitative positron emission tomography (PET) parameters and intratumoral heterogeneity (ITH) on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging and survival data of non-metastatic triple-negative breast cancer (TNBC) patients.
Methods
Sixty-two consecutive female patients who underwent pretreatment 18F-FDG PET/CT with non-metastatic TNBC were enrolled. Heterogeneity index (HI) variables derived from the metabolic tumor volume (MTV) and standardized uptake value (SUV) parameters of primary lesions were evaluated. A novel modified method introducing a percentage-based (30-40-50%) MTV slope comparison was proposed. The association between conventional 18F-FDG PET/CT parameters, HI values, and survival results was analyzed retrospectively.
Results
Tumors with higher HI values were associated with shorter survival times. For overall survival (OS), HI2 and HI3 were statistically significant (P=.009, P=.016). Regarding radiological progression-free survival (rPFS), HI1 and HI3 were statistically significant (P=.01, P=.025). A significant weak correlation between HI1 (P=.005, rho=.34) and a strong correlation was found for HI2 (P<.0001, rho=.89), HI3 and tumor size were not statistically significantly correlated (P=.063, rho=.23). T stage was statistically significantly associated with rPFS and OS (P=.038, P=.003). In contrast, no statistically significant difference was found for the N stage, anatomical, and clinical staging (P>.05).
Conclusion
This study concluded that ITH predicts survival for non-metastatic TNBC patients. This conclusion was reached with the heterogeneity index variables obtained by different methods. However, our results revealed that HI2 depends on tumor size. Our modified method (HI3) predicts survival independently of tumor size.
{"title":"Nuevo método de heterogeneidad para predecir la supervivencia en el cáncer de mama triple negativo no metastásico","authors":"G.B. Babacan , M.Ö. Tamam , S. Saraçoğlu , M.N. Acar Tayyar , M.C. Şahin , H. Özçevik , G. Kulduk , Ö.B. Ekinci , E. Çelik","doi":"10.1016/j.remn.2025.500112","DOIUrl":"10.1016/j.remn.2025.500112","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate the relationship between semiquantitative positron emission tomography (PET) parameters and intratumoral heterogeneity (ITH) on <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) imaging and survival data of non-metastatic triple-negative breast cancer (TNBC) patients.</div></div><div><h3>Methods</h3><div>Sixty-two consecutive female patients who underwent pretreatment <sup>18</sup>F-FDG PET/CT with non-metastatic TNBC were enrolled. Heterogeneity index (HI) variables derived from the metabolic tumor volume (MTV) and standardized uptake value (SUV) parameters of primary lesions were evaluated. A novel modified method introducing a percentage-based (30-40-50%) MTV slope comparison was proposed. The association between conventional <sup>18</sup>F-FDG PET/CT parameters, HI values, and survival results was analyzed retrospectively.</div></div><div><h3>Results</h3><div>Tumors with higher HI values were associated with shorter survival times. For overall survival (OS), HI2 and HI3 were statistically significant (<em>P</em>=.009, <em>P</em>=.016). Regarding radiological progression-free survival (rPFS), HI1 and HI3 were statistically significant (<em>P</em>=.01, <em>P</em>=.025). A significant weak correlation between HI1 (<em>P</em>=.005, rho=.34) and a strong correlation was found for HI2 (<em>P</em><.0001, rho=.89), HI3 and tumor size were not statistically significantly correlated (<em>P</em>=.063, rho=.23). T stage was statistically significantly associated with rPFS and OS (<em>P</em>=.038, <em>P</em>=.003). In contrast, no statistically significant difference was found for the N stage, anatomical, and clinical staging (<em>P</em>>.05).</div></div><div><h3>Conclusion</h3><div>This study concluded that ITH predicts survival for non-metastatic TNBC patients. This conclusion was reached with the heterogeneity index variables obtained by different methods. However, our results revealed that HI2 depends on tumor size. Our modified method (HI3) predicts survival independently of tumor size.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500112"},"PeriodicalIF":1.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-10DOI: 10.1016/j.remn.2025.500179
S. López Puche , J.G. Villanueva Curto , P. García-Talavera San Miguel , J.A. Badell Martínez , S. Rama Alonso , M.P. Tamayo Alonso
{"title":"Enfermedad de Erdheim Chester: diagnóstico y valoración de respuesta con PET/TC [18F]FDG","authors":"S. López Puche , J.G. Villanueva Curto , P. García-Talavera San Miguel , J.A. Badell Martínez , S. Rama Alonso , M.P. Tamayo Alonso","doi":"10.1016/j.remn.2025.500179","DOIUrl":"10.1016/j.remn.2025.500179","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500179"},"PeriodicalIF":1.6,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-02DOI: 10.1016/j.remn.2025.500113
G.U. Erdem , O. Vural Topuz , E. Acar , T. Kapagan , E. Yetim , A. Ozmen , S. Gurocak , G. Usul , S. Yuksel , A.H. Yardimci , N. Bulut
Objectives
We evaluated the influence of baseline volumetric 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) parameters and inflammatory prognostic markers on complete response (CR) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (nCRT).
Materials and methods
In total, 90 patients with LARC, including those with and without CR, were evaluated based on baseline volumetric PET/CT parameters, such as maximum standard uptake value, metabolic tumor volume (MTV), tumor lesion glycolysis, and inflammatory prognostic markers, including the lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio.
Results
Of the 90 patients, 62 (68.9%) were male and 28 (31.1%) were female. The median age was 61 (31-81) years. A complete response was observed in 20 (22%) patients following nCRT. Of these, 5 demonstrated a clinical complete response, whereas 15 exhibited a complete response after surgery. A low pretreatment PLR, low MTV levels, and stage 2 disease were identified as significant predictors of complete response. The optimal cutoff values were 16.5 for MTV (sensitivity 80%, specificity 62%) and 121 for PLR (sensitivity 73%, specificity 65%).
Conclusion
Our findings suggest that stage 2 disease, low pretreatment MTV, and low PLR levels may be predictive of a CR to nCRT in patients with LARC.
{"title":"Predicción de la respuesta completa a la quimiorradioterapia neoadyuvante en el cáncer de recto localmente avanzado: papel de los parámetros volumétricos basales de la PET/TC con [18F]FDG y los marcadores inflamatorios","authors":"G.U. Erdem , O. Vural Topuz , E. Acar , T. Kapagan , E. Yetim , A. Ozmen , S. Gurocak , G. Usul , S. Yuksel , A.H. Yardimci , N. Bulut","doi":"10.1016/j.remn.2025.500113","DOIUrl":"10.1016/j.remn.2025.500113","url":null,"abstract":"<div><h3>Objectives</h3><div>We evaluated the influence of baseline volumetric 18F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) parameters and inflammatory prognostic markers on complete response (CR) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (nCRT).</div></div><div><h3>Materials and methods</h3><div>In total, 90 patients with LARC, including those with and without CR, were evaluated based on baseline volumetric PET/CT parameters, such as maximum standard uptake value, metabolic tumor volume (MTV), tumor lesion glycolysis, and inflammatory prognostic markers, including the lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio.</div></div><div><h3>Results</h3><div>Of the 90 patients, 62 (68.9%) were male and 28 (31.1%) were female. The median age was 61 (31-81) years. A complete response was observed in 20 (22%) patients following nCRT. Of these, 5 demonstrated a clinical complete response, whereas 15 exhibited a complete response after surgery. A low pretreatment PLR, low MTV levels, and stage 2 disease were identified as significant predictors of complete response. The optimal cutoff values were 16.5 for MTV (sensitivity 80%, specificity 62%) and 121 for PLR (sensitivity 73%, specificity 65%).</div></div><div><h3>Conclusion</h3><div>Our findings suggest that stage 2 disease, low pretreatment MTV, and low PLR levels may be predictive of a CR to nCRT in patients with LARC.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500113"},"PeriodicalIF":1.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-23DOI: 10.1016/j.remn.2025.500165
E. Noriega-Álvarez , A. Moreno-Ballesteros , M. Velasco Nuño , J.M. Cordero García , J.J. Rosales Castillo , U.V. Schmülling , E. López Rodríguez , A. Rigabert Sánchez-Junco , B. Rodríguez Alfonso
The continued increase in demand for diagnosis and monitoring of infectious bone diseases, along with the introduction of new equipment, radiopharmaceuticals, and techniques for this purpose, has made it necessary to dynamically update the existing protocols and recommendations. Therefore, the MSP-WG conducted a survey for spanish hospitals to complete and develop recommendations in the form of algorithms, in an attempt to combine existing scientific evidence with the reality of national clinical practice.
{"title":"Encuesta nacional sobre la imagen nuclear en patología ósea infecciosa: resultados y recomendaciones diagnósticas del Grupo de Trabajo de Patología Musculoesquelética (GT-PME)","authors":"E. Noriega-Álvarez , A. Moreno-Ballesteros , M. Velasco Nuño , J.M. Cordero García , J.J. Rosales Castillo , U.V. Schmülling , E. López Rodríguez , A. Rigabert Sánchez-Junco , B. Rodríguez Alfonso","doi":"10.1016/j.remn.2025.500165","DOIUrl":"10.1016/j.remn.2025.500165","url":null,"abstract":"<div><div>The continued increase in demand for diagnosis and monitoring of infectious bone diseases, along with the introduction of new equipment, radiopharmaceuticals, and techniques for this purpose, has made it necessary to dynamically update the existing protocols and recommendations. Therefore, the MSP-WG conducted a survey for spanish hospitals to complete and develop recommendations in the form of algorithms, in an attempt to combine existing scientific evidence with the reality of national clinical practice.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500165"},"PeriodicalIF":1.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号